Recent News

• 02.18.2025 - Celyad Oncology announces the publication of the preclinical and clinical data of CYAD-211 providing proof-of-concept of its miRNA-based shRNA platform
• 02.08.2024 - Celyad Oncology announces intention to terminate SEC reporting obligations
• 02.08.2024 - Celyad Oncology announces intention to terminate SEC reporting obligations
• 01.16.2024 - Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
• 01.16.2024 - Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
• 12.20.2023 - Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
• 12.20.2023 - Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
• 12.15.2023 - Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
• 12.15.2023 - Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
• 12.04.2023 - Celyad announces management change

Recent Filings

• 02.09.2024 - 15F-12B Securities registration termination of foreign private issuers [Section 12(b)]
• 01.17.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.21.2023 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.18.2023 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.04.2023 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.04.2023 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.24.2023 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]